Baxter International vs ResMed
BAX and RMD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BAX and RMD compare
ResMed is the larger company, worth 2.8 times as much as Baxter International ($33.2B against $11.9B).
ResMed grew revenue faster over the last twelve months (9.9% versus 5.3% for Baxter International).
ResMed keeps more of each dollar of sales as profit, with a net margin of 26.9% compared with −6.2% at Baxter International.
Both pay dividends: Baxter International yields 0.17% and ResMed 1.1%.
ResMed scores higher on the StockData Score (21 against 11 for Baxter International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BAX | RMD |
|---|---|---|
| Size and price | ||
| Market cap | $11.9B | $33.2B |
| Share price | $23.00 | $229.94 |
| Change, 1 year | 2.6% | −9.3% |
| Change, 5 years | −70.5% | −11.7% |
| Beta (5Y) | 0.81 | 0.91 |
| Employees | 38K | 11K |
| StockData Score | ||
| Total score | 11 | 21 (better) |
| Valuation score | 3 | 4 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 2 | 6 (better) |
| Health score | 4 | 4 |
| Dividend score | 1 | 4 (better) |
| Valuation | ||
| P/E | – | 22.0× |
| P/S | 1.0× (better) | 5.9× |
| P/B | 1.8× (better) | 5.0× |
| EV/EBITDA | 14.6× (better) | 15.3× |
| P/FCF | – | 20.1× |
| PEG | – | 1.12 |
| FCF yield | – | 5.0% |
| Fair value | $24.60 | $259.82 |
| Margin of safety | 6.5% | 11.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 5.3% | 9.9% (better) |
| Revenue growth, 5Y average | −0.75% | 12.1% (better) |
| Net income growth (TTM) | – | 8.8% |
| EPS growth (TTM) | – | 9.7% |
| EPS growth, 5Y average | – | 26.3% |
| Profitability | ||
| Gross margin | 30.1% | 61.1% (better) |
| Operating margin | −1.9% | 33.4% (better) |
| Net margin | −6.2% | 26.9% (better) |
| FCF margin | – | 29.2% |
| Return on equity | −10.5% | 24.3% (better) |
| Return on invested capital | −3.0% | 29.5% (better) |
| Financial health | ||
| Debt / equity | 0.13 | 0.04 (better) |
| Net debt / EBITDA | −1.54 | −0.58 |
| Interest coverage | −0.8× | – |
| Current ratio | 1.79 | 3.10 (better) |
| Altman Z-score | 2.31 | 11.21 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.17% | 1.1% (better) |
| Payout ratio | – | 23.0% |
| Years of dividend growth | 0 | 5 (better) |
| Dividend growth, 5Y average | −11.4% | 9.0% (better) |
| Buyback yield | – | 1.9% |
| Shareholder yield | 0.17% | 3.0% (better) |
| Ownership | ||
| Held by institutions | 108% | 69.4% |
| Held by insiders | 0.58% | 1.3% |
| Insider net buying, 12 months | – | −$21.1M |
| Superinvestors holding | 2 (better) | 1 |
| Short interest, % of float | 4.7% | – |
Go deeper
- BAX stock overview
- BAX income statement
- BAX valuation and score
- RMD stock overview
- RMD income statement
- RMD valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.